SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS

被引：0
|
作者：
Deodhar, Atul [1 ]
Baeten, Dominique [2 ]
Blanco, Ricardo [3 ]
Sieper, Joachim [4 ]
Martin, Ruvie [5 ]
Porter, Brian [5 ]
Richards, Hanno [6 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Hosp Marques Valdecilla, Madrid, Spain
[4] Charite Univ Med Berlin, Berlin, Germany
[5] Novartis Pharmaceut, New York, NY USA
[6] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3287369
引用
收藏
页码：137 / 138
页数：2
相关论文
共 42 条
  • [21] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Zuazo, J.
    Readie, A.
    Porter, B.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 812 - 813
  • [22] Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
    Kivitz, Alan J.
    Pavelka, Karel
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Wang, Yi
    Porter, Brian
    Stefanska, Anna
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [23] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE-2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Martin, R.
    Readie, A.
    Richards, H.
    Porter, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 783 - 783
  • [24] Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)
    Wei, J. C. C.
    Baeten, D.
    Sieper, J.
    Deodhar, A.
    Bhosekar, V
    Martin, R.
    Porter, B.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (07) : 911 - 911
  • [25] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: THREE-YEAR RESULTS FROM PHASE 3 TRIAL, MEASURE 2
    Tahir, Hasan
    Marzo-Ortega, Helena
    Legerton, Clarence W.
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno B.
    RHEUMATOLOGY, 2018, 57
  • [26] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE 3 TRIAL, MEASURE 2
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Richardo
    Cohen, Martin
    Delicha, Eumorphia-Maria
    Rohrer, Susanne
    Richards, Hanno
    RHEUMATOLOGY, 2019, 58
  • [27] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 3-YEAR RESULTS FROM PHASE III TRIAL, MEASURE 2
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A. J.
    Blanco, R.
    Cohen, M.
    Delicha, E. M.
    Rohrer, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 345 - 345
  • [28] Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
    Braun, Juergen
    Deodhar, Atul A.
    Sieper, Joachim
    Dougados, Maxime
    Porter, Brian
    Andersson, Mats
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [29] SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE III TRIAL, MEASURE 2
    Marzo-Ortega, H.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Delicha, E. M.
    Rohrer, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1005 - 1005
  • [30] SECUKINUMAB PROVIDES SIGNIFICANT AND SUSTAINED IMPROVEMENT IN NAIL PSORIASIS AND SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WITH NAIL PHENOTYPE: 52-WEEK RESULTS FROM THE PHASE III FUTURE 5 STUDY
    Nash, Peter
    Mease, Philip J.
    Kirkham, Bruce
    Balsa, Alejandro
    Singhal, Atul
    Quebe-Fehling, Erhard
    Pricop, Luminita
    Gaillez, Corine
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 921 - +
12345